Welcome to to the Irish Medical Times website
This site is aimed at healthcare professionals.
Are you a healthcare professional?
Yes
No
This site contains information, news and advice for healthcare professionals.
You have informed us that you are not a healthcare professional and therefore we are unable to provide you with access to this site.

April 26, 2015

Risk of severe allergic reactions with ambroxol and bromhexine-containing medicines considered small

The European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) has completed a review of the safety of ambroxol and bromhexine-containing medicines*.  Ambroxol and bromhexine are indicated for mucolytic therapy in patients with short or long-term respiratory conditions. Ambroxol lozenges are available for pain relief of sore throats. The majority of these medicines are available over-the-counter […]

Management of Chronic Obstructive Pulmonary Disease

Download PDF Symptoms and airflow limitation should both be taken into account to guide the management of chronic obstructive pulmonary disease (COPD). Airflow limitation, which is linked to the frequency of exacerbations and measure future risks, has poor correlation with the daily impact of the disease upon the individual patient, and therefore serves as little […]

Algorithm for the Pharmaceutical Management of COPD

Download PDF     Reference: [adapted from] Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Updated 2015. Available at: http://www.goldcopd.com

COPD and its Differential Diagnoses: Suggestive Features*

Download PDF COPD: Mid-life onset Slowly progressing symptoms History of tobacco smoking/exposure to smoke from home cooking, heating fuels or to occupational dusts or chemicals Asthma: Early onset in life (often childhood) Varying symptoms from day to day Symptoms worse at night/early morning Presence of allergy, rhinitis, and/or eczema Family history of asthma Airflow limitation […]

Beta interferons – Risk of thrombotic microangiopathy and nephrotic syndrome

Interferon beta-1a and interferon beta-1b are indicated for the treatment of relapsing multiple sclerosis* and in patients with a single demyelinating event with an active inflammatory process. Interferon beta-1b products may also be used in patients with secondary progressive multiple sclerosis with active disease evidenced by relapses. In July 2014, a European review of interferon […]

AirFluSal Forspiro

Company: Rowex Ltd. Legal category: Prescription. GMS. Sport restricted beta agonists. Active ingredients: Salmeterol (as xinafoate)/fluticasone propionate 50/250mcg, 50/500mcg. Description: Pre-dispensed inhalation powder. Presentation: 50/250mcg-60 dose unit, €29.32; 50/500mcg-60 dose unit, €38.34. Indications: Asthma (both strengths): Regular treatment of asthma where use of a combination product (long-acting beta-2-agonist and inhaled corticosteroid) is appropriate. COPD (50/500mcg […]

REZOLSTA ▼

Company: Janssen-Cilag Ltd. Legal category: Prescription. Hospital. Sport permitted. Active ingredients: Darunavir (as ethanolate)/cobicistat 800/150mg. Description: Pink, oval, film-coated tablet marked 800 on one side and TG on reverse. Presentation: 30, €509.53. Indication: Treatment of human immunodeficiency virus-1 (HIV-1) infection in combination with other antiretrovirals. In antiretroviral therapy (ART)-experienced adults without darunavir resistance associated mutations […]

Colomycin 2 mega units

Company: Actavis Ireland Ltd. Legal category: Prescription. GMS. Sport permitted. Active ingredient: Colistimethate sodium 2 mega units. Description: Powder for solution for injection, infusion or inhalation in vial with lilac cap. Presentation: 10, €42.56. Indications: Treatment by inhalation, for Pseudomonas aeruginosa lung infection in patients with cystic fibrosis (CF). Treatment by intravenous (IV) administration, for […]

Copaxone 40mg/ml

Company: Teva Pharmaceuticals Ireland. Legal category: Prescription. High Tech. Sport permitted. Active ingredient: Glatiramer acetate 40mg/ml (equivalent to 36mg glatiramer base). Description: Solution for injection. Presentation: 12 pre-filled syringes, €848.45. Indication: Treatment of relapsing forms of multiple sclerosis (MS). Pharmacology: The mechanism by which glatiramer acetate exerts its effects is not fully elucidated. It is […]

Peripheral Arterial Disease

Download PDF “The identification and appropriate management of this often unidentified, high risk patient group, represents a significant opportunity in general practice to improve survival and reduce the risk of heart attack and stroke.”1 Summary Peripheral arterial disease (PAD), a manifestation of systemic atherosclerosis, most commonly presents in the lower limbs, but also serves as […]

Next Page »